EBS
insider transactionsEmergent BioSolutions Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-65.9K
0 buy · 65.9K sell
Net value · 90d
-$552.0K
$0 in · $552.0K out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
8
0 buy · 65.9K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Other·F
SVP, Bioservices
$13.9K
1.7K sh · $8.00
Own -1%
-
Other·F
SVP, Products Business
$5.6K
694 sh · $8.00
Own -0%
-
Other·F
EVP, Quality & Ethics, and CPL
$16.1K
2.0K sh · $8.00
Own -1%
-
Other·F
EVP, Chief Financial Officer
$31.7K
4.0K sh · $8.00
Own -1%
-
Sell·S
Director · 10b5-1
$9.5K
1.1K sh · $8.97
Own -1%
-
Sell·S
Director · 10b5-1
$135.0K
16.1K sh · $8.36
Own -17%
-
Sell·S
Director · 10b5-1
$8.5K
954 sh · $8.96
Own -1%
-
Sell·S
Director · 10b5-1
$121.4K
14.5K sh · $8.36
Own -10%
-
Sell·S
Director · 10b5-1
$8.8K
980 sh · $8.94
Own -1%
-
Sell·S
Director · 10b5-1
$106.8K
12.8K sh · $8.36
Own -11%
-
Grant·A
Director · 10b5-1
$0
11.3K sh
Own New
-
Grant·A
Director · 10b5-1
$0
25.3K sh
Own +35%
-
Grant·A
Director
$0
11.3K sh
Own New
-
Grant·A
Director
$0
25.3K sh
Own +19%
-
Grant·A
Director
$0
11.3K sh
Own New
-
Grant·A
Director
$0
25.3K sh
Own +29%
-
Grant·A
Zsolt Harsanyi KEY
Chairman
$0
11.3K sh
Own New
-
Grant·A
Zsolt Harsanyi KEY
Chairman
$0
25.3K sh
Own +20%
-
Grant·A
Director
$0
11.3K sh
Own New
-
Grant·A
Director
$0
25.3K sh
Own +26%
-
Grant·A
Director · 10b5-1
$0
11.3K sh
Own New
-
Sell·S
Director · 10b5-1
$128.2K
15.5K sh · $8.28
Own -14%
-
Grant·A
Director · 10b5-1
$0
25.3K sh
Own +29%
-
Grant·A
Director
$0
11.3K sh
Own New
-
Grant·A
Director
$0
25.3K sh
Own +506%
-
Grant·A
Director · 10b5-1
$0
11.3K sh
Own New
-
Grant·A
Director · 10b5-1
$0
25.3K sh
Own +21%
-
Grant·A
Director · 10b5-1
$0
11.3K sh
Own New
-
Grant·A
Director · 10b5-1
$0
25.3K sh
Own +28%
-
Grant·A
SVP, R&D, CMO
$0
100.1K sh
Own +129%
-
Grant·A
SVP, General Counsel, Corp Sec
$0
104.3K sh
Own +171%
-
Grant·A
SVP, Bioservices
$0
100.1K sh
Own +115%
-
Grant·A
SVP, Products Business
$0
100.1K sh
Own +160%
-
Grant·A
EVP, Quality & Ethics, and CPL
$0
100.1K sh
Own +96%
-
Grant·A
Joseph C Papa KEY
President and CEO
$0
187.7K sh
Own +61%
-
Grant·A
EVP, Chief Financial Officer
$0
162.7K sh
Own +76%
-
Sell·S
SVP, Products Business · 10b5-1
$33.8K
4.0K sh · $8.44
Own -6%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 8, 2026 | William Hartzel | Other F | 1.7K | $13.9K |
| Jun 8, 2026 | Paul Anthony Williams | Other F | 694 | $5.6K |
| Jun 8, 2026 | Coleen Glessner | Other F | 2.0K | $16.1K |
| Jun 8, 2026 | Richard S Lindahl KEY | Other F | 4.0K | $31.7K |
| May 1, 2026 | Kathryn C Zoon 10b5-1 | Sell S | 1.1K | $9.5K |
| May 1, 2026 | Kathryn C Zoon 10b5-1 | Sell S | 16.1K | $135.0K |
| May 1, 2026 | Donald W Degolyer 10b5-1 | Sell S | 954 | $8.5K |
| May 1, 2026 | Donald W Degolyer 10b5-1 | Sell S | 14.5K | $121.4K |
| May 1, 2026 | Sujata Tyagi Dayal 10b5-1 | Sell S | 980 | $8.8K |
| May 1, 2026 | Sujata Tyagi Dayal 10b5-1 | Sell S | 12.8K | $106.8K |
| Apr 30, 2026 | Kathryn C Zoon 10b5-1 | Grant A | 11.3K | $0 |
| Apr 30, 2026 | Kathryn C Zoon 10b5-1 | Grant A | 25.3K | $0 |
| Apr 30, 2026 | Neal Franklin Fowler | Grant A | 11.3K | $0 |
| Apr 30, 2026 | Neal Franklin Fowler | Grant A | 25.3K | $0 |
| Apr 30, 2026 | Marvin L White | Grant A | 11.3K | $0 |
| Apr 30, 2026 | Marvin L White | Grant A | 25.3K | $0 |
| Apr 30, 2026 | Zsolt Harsanyi KEY | Grant A | 11.3K | $0 |
| Apr 30, 2026 | Zsolt Harsanyi KEY | Grant A | 25.3K | $0 |
| Apr 30, 2026 | Ronald Richard | Grant A | 11.3K | $0 |
| Apr 30, 2026 | Ronald Richard | Grant A | 25.3K | $0 |
| Apr 30, 2026 | Keith Katkin 10b5-1 | Grant A | 11.3K | $0 |
| Apr 30, 2026 | Keith Katkin 10b5-1 | Sell S | 15.5K | $128.2K |
| Apr 30, 2026 | Keith Katkin 10b5-1 | Grant A | 25.3K | $0 |
| Apr 30, 2026 | John D Fowler JR | Grant A | 11.3K | $0 |
| Apr 30, 2026 | John D Fowler JR | Grant A | 25.3K | $0 |
| Apr 30, 2026 | Donald W Degolyer 10b5-1 | Grant A | 11.3K | $0 |
| Apr 30, 2026 | Donald W Degolyer 10b5-1 | Grant A | 25.3K | $0 |
| Apr 30, 2026 | Sujata Tyagi Dayal 10b5-1 | Grant A | 11.3K | $0 |
| Apr 30, 2026 | Sujata Tyagi Dayal 10b5-1 | Grant A | 25.3K | $0 |
| Apr 29, 2026 | Simon C Lowry | Grant A | 100.1K | $0 |
| Apr 29, 2026 | Jessica Perl | Grant A | 104.3K | $0 |
| Apr 29, 2026 | William Hartzel | Grant A | 100.1K | $0 |
| Apr 29, 2026 | Paul Anthony Williams | Grant A | 100.1K | $0 |
| Apr 29, 2026 | Coleen Glessner | Grant A | 100.1K | $0 |
| Apr 29, 2026 | Joseph C Papa KEY | Grant A | 187.7K | $0 |
| Apr 29, 2026 | Richard S Lindahl KEY | Grant A | 162.7K | $0 |
| Apr 1, 2026 | Paul Anthony Williams 10b5-1 | Sell S | 4.0K | $33.8K |
About EBS insider trading
This page tracks insider transactions for Emergent BioSolutions Inc. (EBS) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.